News
AVRO
--
0.00%
--
AVROBIO to Present at Three Upcoming Investor Conferences in March
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in three upcoming virtual ...
Business Wire · 1d ago
Mizuho Securities Thinks Avrobio’s Stock is Going to Recover
In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Avrobio (AVRO), with a price target of $43.00. The company's
SmarterAnalyst · 3d ago
Mizuho Securities Thinks Avrobio’s Stock is Going to Recover
In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Avrobio (AVRO), with a price target of $43.00. The company's
SmarterAnalyst · 02/17 09:15
SOS, WPG, CAN and BLUE among midday movers
Gainers: Luokung Technology (LKCO) +112%.Kubient (KBNT) +63%.SOS (SOS) +58%.Torchlight Energy Resources (TRCH) +54%.Protective Insurance (PTVCB) +53%.500.com (WBAI) +45%.ALJ Regional (ALJJ) +45%.Urban Tea (MYT) +44%.Canaan (CAN) +36%.Applied Genetic Techno...
Seekingalpha · 02/16 17:37
bluebird bio trial suspension hurts Orchard and AVROBIO
Before the open, bluebird bio ([[BLUE]] -33.6%) announced it was suspending two Phase 1/2 clinical trials for the gene therapy candidate, LentiGlobin in sickle cell disease (“SCD”)The investigations were ongoing
Seekingalpha · 02/16 17:30
The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12)
Benzinga · 02/12 13:10
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11)
Benzinga · 02/11 12:26
Mizuho Securities Reaffirms Their Buy Rating on Avrobio (AVRO)
Mizuho Securities analyst Difei Yang reiterated a Buy rating on Avrobio (AVRO) today and set a price target of $43.00. The company's shares closed last
SmarterAnalyst · 02/09 09:15
--Analyst Actions: Wedbush Adjusts AVROBIO's Price Target to $40 From $36, Keeps Outperform Rating
MT Newswires · 02/09 06:34
Avrobio reports 100% kidney substrate reduction with plato gene therapy in Fabry disease, shares up 20%
Avrobio (AVRO) jumps 20% premarket following an announcement of 100% reduction, or complete clearance, of toxic substrate in the kidney biopsy of the first patient dosed with the plato gene therapy platform in Phase
Seekingalpha · 02/08 13:11
Avrobio Shares Rally On Fabry Disease Gene Therapy Encouraging Benefit In Early-Stage Study
Benzinga · 02/08 13:07
AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial
Consistent with the 87% reduction in the first evaluable kidney biopsy, there is complete clearance of Gb3 inclusions in second evaluable kidney biopsy in Fabry disease Phase 2 trial New Gaucher disease type 1 Phase
Benzinga · 02/08 12:06
Avrobio Study Shows Potential of Treatment Candidate for Rare Genetic Disease; Shares Climb
MT Newswires · 02/08 09:55
The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight
Biopharma stocks advanced in the week ended Feb. 5, driven higher by a slew of catalysts. Large-cap pharma earnings, vaccine updates, M&A activity, IPO news flow and follow-on offerings all served to lift stocks higher.
Benzinga · 02/06 17:42
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 10,250 shares ...
Business Wire · 02/05 21:05
AVROBIO Announces Multiple Clinical Data Presentations, Posters and Events at 17th Annual WORLDSymposium™ 2021
BusinessWire - BZX · 02/02 08:22
AVROBIO Announces Multiple Clinical Data Presentations, Posters and Events at 17th Annual WORLDSymposium 2021
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will host a virtual investor event to discuss new data from AVROBIO’s clinical programs in...
Business Wire · 02/01 12:00
AVROBIO Announces Multiple Clinical Data Presentations, Posters and Events at 17th Annual WORLDSymposium 2021
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will host a virtual investor event to discuss new data from AVROBIO’s clinical programs in...
Business Wire · 02/01 12:00
AVROBIO to Present at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit
Business Wire · 01/22 12:00
AVROBIO to Present at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit
AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Azadeh Golipour, VP of Manufacturing Operations at AVROBIO, will present virtually at the Cowen 202...
Business Wire · 01/22 12:00
Webull provides a variety of real-time AVRO stock news. You can receive the latest news about AVROBIO through multiple platforms. This information may help you make smarter investment decisions.
About AVRO
AVROBIO, Inc. is a clinical-stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its product pipeline includes AVR-RD-01, AVR-RD-02, AVR-RD-03 and AVR-RD-04. The Company is developing AVR-RD-01 for the treatment of Fabry disease. AVR-RD-02 is the Company’s gene therapy for Gaucher disease. AVR-RD-03 is being developed for the treatment of Pompe disease. The Company is developing AVR-RD-04 for the treatment of patients with cystinosis.